Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D

Abstract excerpt

Recombinant adenovirus serotype 5 (rAd5) vector-based vaccines are currently being developed for both human immunodeficiency virus type 1 and other pathogens. The potential limitations associated with rAd5 vectors, however, have led to the construction of novel rAd vectors derived from rare Ad serotypes. Several rare serotype rAd vectors have already been described, but a detailed comparison of multiple rAd...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Herpesvirus Infections and Treatments
• Share to Viral Infections and Outbreaks Research
• Share to Virus-based gene therapy research